Literature DB >> 20372790

Induction of apoptosis in glioma cells requires cell-to-cell contact with human umbilical cord blood stem cells.

Christopher S Gondi1, Venkateswara R Gogineni, Chandramu Chetty, Venkata R Dasari, Bharathi Gorantla, Meena Gujrati, Dzung H Dinh, Jasti S Rao.   

Abstract

We have previously demonstrated the multipotent nature of human umbilical cord blood stem cells (hUCB). In this study, we have attempted to show the use of hUCB in glioma therapy. We used hUCB enriched in CD44 and CD133 cells for our studies and observed that glioma cells co-cultured with hUCB undergo apoptosis. To prove the role of cell-to-cell contact in the induction of apoptotic events, we used a modified 0.22 microm Boyden's chamber where the upper surface was used to culture glioma cells (SNB19 or U87) or xenografts (4910 or 5310) and the lower surface to culture hUCB. TUNEL assay was carried out to determine the degree of apoptotic induction and we observed that glioma or xenograft cells co-cultured with hUCB had a higher number of TUNEL-positive characteristics (63+/-6%) compared to the controls. Further, we co-cultured glioma cells labeled with lipophilic green fluorescent dye and hUCB labeled with lipophilic red fluorescent dye. FACS analysis of cells collected from the upper and lower surfaces revealed that glioma cells had taken up red fluorescent dye from the stem cells (70+/-3%) when compared to glioma cells co-cultured with fibroblast cells (15+/-4%). The apoptotic events in the glioma and xenograft cells co-cultured with hUCB were also confirmed by Western blot analysis for the cleavage of PARP and activation of caspase 8. In addition, elevated levels of CHK-2 levels and downregulation of MAP2K1 were observed in glioma cells co-cultured with hUCB indicating the DNA damage and decrease in cell survival. Nude mice, intracranially implanted with luciferase-expressing U87 cells followed by implantation of hUCB or human fibroblast cells showed retardation of intracranial tumors in hUCB-implanted mice. Taken together, these results demonstrate that hUCB have therapeutic potential with possible clinical implications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372790      PMCID: PMC2852191          DOI: 10.3892/ijo_00000599

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  39 in total

Review 1.  PDZ domains: More than just a glue.

Authors:  I Bezprozvanny; A Maximov
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

Review 2.  Can stem cells cross lineage boundaries?

Authors:  D J Anderson; F H Gage; I L Weissman
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

Review 3.  Diversity in protein recognition by PTB domains.

Authors:  J D Forman-Kay; T Pawson
Journal:  Curr Opin Struct Biol       Date:  1999-12       Impact factor: 6.809

4.  Mesenchymal progenitor cells in human umbilical cord blood.

Authors:  A Erices; P Conget; J J Minguell
Journal:  Br J Haematol       Date:  2000-04       Impact factor: 6.998

5.  Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers.

Authors:  H S Goodwin; A R Bicknese; S N Chien; B D Bogucki; C O Quinn; D A Wall
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

6.  From marrow to brain: expression of neuronal phenotypes in adult mice.

Authors:  T R Brazelton; F M Rossi; G I Keshet; H M Blau
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

Review 7.  Status of umbilical cord blood transplantation in the year 2001.

Authors:  J M Hows
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

Review 8.  Signal-dependent membrane targeting by pleckstrin homology (PH) domains.

Authors:  M A Lemmon; K M Ferguson
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

9.  Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation.

Authors:  Chanran Ganta; Doi Chiyo; Rie Ayuzawa; Rajashekar Rachakatla; Marla Pyle; Gordon Andrews; Mark Weiss; Masaaki Tamura; Deryl Troyer
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

10.  CD44 is a major E-selectin ligand on human hematopoietic progenitor cells.

Authors:  C J Dimitroff; J Y Lee; S Rafii; R C Fuhlbrigge; R Sackstein
Journal:  J Cell Biol       Date:  2001-06-11       Impact factor: 10.539

View more
  5 in total

1.  The homing of human cord blood stem cells to sites of inflammation: unfolding mysteries of a novel therapeutic paradigm for glioblastoma multiforme.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Jasti S Rao
Journal:  Cell Cycle       Date:  2012-06-15       Impact factor: 4.534

2.  Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.

Authors:  Venkata Ramesh Dasari; Kiranpreet Kaur; Kiran Kumar Velpula; Meena Gujrati; Daniel Fassett; Jeffrey D Klopfenstein; Dzung H Dinh; Jasti S Rao
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

3.  Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Andrew J Tsung; Christopher S Gondi; Jeffrey D Klopfenstein; Sanjeeva Mohanam; Jasti S Rao
Journal:  PLoS One       Date:  2011-03-24       Impact factor: 3.240

4.  The role of stem cells in tumor targeting and growth suppression of gliomas.

Authors:  Hossein Eskandary; Mohsen Basiri; Seyed Noureddin Nematollahi-Mahani; Sepideh Mehravaran
Journal:  Biologics       Date:  2011-04-05

5.  Umbilical cord tissue-derived mesenchymal stem cells induce apoptosis in PC-3 prostate cancer cells through activation of JNK and downregulation of PI3K/AKT signaling.

Authors:  Ihn Han; Miyong Yun; Eun-Ok Kim; Bonglee Kim; Min-Hyung Jung; Sung-Hoon Kim
Journal:  Stem Cell Res Ther       Date:  2014-04-16       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.